Capstone Therapeutics Corp. 2019 Q1 SEC Filing Summary
Reporting period: Three months ended March 31, 2019; filed May 13, 2019. The filing identifies the registrant as Capstone Therapeutics Corp., although the request metadata identifies Capstone Holding Corp.
Business Context
The company is a biotechnology business focused on developing peptide therapeutics. Its primary current program is AEM-28 and related Apo E mimetic analogs, pursued through approximately 60%-owned LipimetiX Development, Inc. The company operates as a single reportable segment and has no commercial revenue-producing operations. Development activities have been substantially reduced because additional funding is required.
Key Financial Metrics
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| Sublicense revenue | $0 | $0 | No change |
| General and administrative expense | $188,000 | $229,000 | Down $41,000 |
| Research and development expense | $601,000 | $301,000 | Up $300,000 |
| Total operating expenses | $789,000 | $530,000 | Up $259,000 |
| Net loss attributable to shareholders | $855,000 | $587,000 | Higher loss of $268,000 |
| Loss per basic and diluted share | $0.02 | $0.01 | Higher loss per share |
| Cash flow used in operations | $299,000 | $470,000 | Improved by $171,000 |
There was no meaningful operating margin because the company generated no revenue and incurred operating expenses. Interest and other expense was $63,000, compared with $60,000 in the prior-year quarter. Cash declined from $1.341 million at December 31, 2018 to $1.092 million at March 31, 2019; approximately $940,000 of the March 31 cash balance was held by the joint venture.
Total assets were $1.221 million, including $1.221 million of current assets. Current liabilities were $732,000, and secured debt and accrued interest totaled $2.584 million. Stockholders’ equity was negative $2.095 million, compared with negative $1.244 million at December 31, 2018.
Material Changes Versus the Prior Comparable Period
- Research and development expense doubled to $601,000, primarily reflecting activity under the ANJI cooperation agreement and the availability of funds from the 2018 sublicense payment.
- General and administrative expense declined, mainly because of lower joint venture patent legal fees.
- Net loss increased approximately 46% to $855,000, despite a $171,000 improvement in operating cash burn.
- The company borrowed an additional $50,000 under its Brookstone secured financing facility in March 2019.
- The March 2019 balance sheet reflects adoption of the lease standard, resulting in a $28,000 right-of-use asset and corresponding lease liability; management reported no material overall effect.
- The company had 54,385,411 common shares outstanding at March 31, 2019 and May 1, 2019. Brookstone owned approximately 34.1% of the outstanding common stock at March 31, 2019.
Guidance, Outlook, Risks, and Unusual Items
The company expects to maintain a virtual operating model and limit development activities while pursuing fundraising, partnering, licensing, strategic transactions, or debt or equity financing. Management states that the company and its joint venture do not currently have sufficient funds for additional material development activities. No quantitative earnings or revenue guidance was provided.
- The company requires additional capital to continue operations and to advance AEM-28 and its analogs through further clinical, regulatory, research, and manufacturing work.
- The Brookstone secured loan bears interest at 6%, is secured by all company assets, and is due October 15, 2020. Accrued interest is payable at maturity. The March 2019 amendment permits up to $500,000 of additional borrowing, potentially increasing to $700,000 at Brookstone’s discretion.
- The joint venture’s revolving loan balance, including accrued interest, was $1.740 million at March 31, 2019, with repayment generally due July 15, 2020, subject to earlier repayment provisions.
- The ANJI sublicense generated a $2.0 million payment in the second quarter of 2018, but there was no sublicense revenue in the first quarter of 2019 or 2018. Future royalties and milestone payments are contingent on future development and commercial events.
- If the company or joint venture cannot obtain funding, AEM-28 development and operations could be impaired. The company disclosed potential additional exposure of $667,000 for losses previously allocated to joint venture noncontrolling interests if the joint venture does not continue as a going concern.
- Key risks include clinical or preclinical failure, regulatory delays or denial, competition, intellectual-property impairment, inability to secure partnering or financing, reliance on a virtual operating model, and potential loss of OTCQB listing.
- Management reported no material legal loss contingency and stated that disclosure controls were effective as of March 31, 2019.
Investor Verification Items
- Verify the company’s near-term cash runway using the $1.092 million cash balance, $299,000 quarterly operating cash use, restricted availability of joint venture cash, and expected administrative obligations.
- Review the terms, collateral, maturity, interest accrual, and remaining availability of the Brookstone secured debt and the potential dilution from related warrants.
- Confirm the status and funding requirements of LipimetiX Development, Inc. and the development timetable for AEM-28 and its analogs.
- Assess whether additional financing, licensing, or strategic transactions are likely and the potential effect on existing shareholders.
- Verify the economic value and collectability of future ANJI sublicense royalties and milestones, since no recurring sublicense revenue was recorded in the quarter.
- Reconcile the filing’s references to company and joint venture ownership percentages, debt balances, accrued obligations, and unpaid officer or service-provider compensation.